Navigation Links
La Jolla Institute scientist discovers key step in immune system-fueled inflammation
Date:7/1/2012

SAN DIEGO (July 1, 2012) Like detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells. The finding provides powerful, previously unknown information about critical biological mechanisms underlying heart disease and many other disorders.

The study, published today in Nature, focuses on one of the body's most abundant and important immune cells, known as neutrophils, which play a pivotal role in many diseases. "Neutrophils are the body's first line of defense and the main cell protecting us from bacterial infections," said Dr. Ley, a pioneer in vascular immunology and head of the La Jolla Institute's Division of Inflammation Biology. "While their protective function is very positive, neutrophils also have inflammation-producing properties that cause problems in heart disease and a host of autoimmune diseases, for example lupus. This makes understanding how to manipulate these cells extremely important in disrupting disease."

National Medal of Science winner Shu Chien, M.D., Ph.D., a UC San Diego professor renowned for his work on vascular mechanisms and atherosclerosis, praised Dr. Ley's finding as a significant advance in understanding inflammatory mechanisms in disease. "They have elucidated the molecular and mechanical bases of this type of neutrophil rolling (in the blood vessels) that have major significance in inflammation," said Dr. Chien, director of UCSD's Institute of Engineering in Medicine. "Since inflammation is at the root of a large variety of diseases, these findings not only have fundamental importance in the mechanobiology of the cell, but also in understanding the pathophysiology of many disease states."

In his Nature paper entitled "'Slings' enable neutrophil rolling at high shear," Dr. Ley revealed how neutrophils use sling-like membrane tethers to latch on to the blood vessel wall during periods when blood flow is very fast. In making the discovery, Dr. Ley and Prithu Sundd, Ph.D., a researcher at La Jolla Institute, used "dynamic footprinting," a pioneering imaging technique they developed in 2010 that uses special microscopes and total internal reflection microscopy to see and photograph the neutrophil adhesion process with unprecedented clarity. Alex Groisman, Ph.D., an associate professor in UCSD's Department of Physics, was instrumental in developing and constructing the microfluidic device in which these experiments were conducted and collaborated on the Nature paper.

Sussan Nourshargh, Ph.D., professor of Microvascular Pharmacology and head of the Center for Microvascular Research at Barts and The London Medical School, University of London, said the work provides another "major insight" from Dr. Ley whose discoveries, over the years, have repeatedly enhanced scientific understanding of the role of neutrophils in causing inflammation. In particular, she cited Dr. Ley's groundbreaking work on the discovery of the leukocyte adhesion cascade, which explained the sequential steps used by neutrophils to clamp onto the blood vessel wall as they prepare to migrate to sites of infection. His latest finding reveals another important step in that process.

"This is a completely new cellular concept that will now be added as an additional step to the leukocyte adhesion cascade that describes the sequential cellular responses involved in guiding neutrophils to sites of inflammation," she said. "This pioneering work will without doubt pave the way for other researchers to explore the occurrence of "slings" in a wide range of inflammatory scenarios."

Like other immune cells, neutrophils travel throughout the body via the blood stream pursuing their infection-fighting duties. In order to accomplish their work, neutrophils must migrate through the blood vessel walls to sites of infection, injury or inflammation.

"The activities of neutrophils are very important for our survival, so they are the subject of significant scientific study," said Dr. Ley. While some scientists study their migration out of the blood vessel, Dr. Ley's lab has focused on how neutrophils adhere to the blood vessel wall. "This is important because it provides an opportunity to develop new treatments based on modulating or blocking one of the steps in the adhesion cascade," said Dr. Ley, noting that earlier studies have shown that blocking even one of the steps can severely reduce neutrophil recruitment.

While Dr. Ley has previously shown how neutrophils adhere when blood flow is slow, his latest study reveals that neutrophils use long membrane tethers at the front of the cell, termed "slings," to slow down during high blood flow. The cells do this by separating their cytoskeleton from the cellular membrane, wrapping the sling around themselves like a lasso and then digging their hooks into the blood vessel wall, said Dr. Ley. High blood flow occurs during inflammation, when the body rushes immune cells to a site to promote healing. Inflammation is a normal part of the healing process, but is unwanted in certain diseases.

"For these cells, adhering under high shear is like being in a huge wind storm," said Dr. Ley. "The challenge in this storm is not to get blown away."

Dr. Ley's studies could prove valuable in helping scientists understand how to reduce adhesion, where inflammation is unwanted, such as in heart or autoimmune disease, or to enhance the process, where more neutrophils are desired, such as in bacterial infections like MRSA. "The body needs to have enough neutrophils to fight off bacteria faster than they can grow," he said. "Better understanding of neutrophil adhesion could be very beneficial in that process. Conversely, interrupting this process could have major impacts in autoimmune and other inflammatory diseases."


'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Related biology news :

1. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
2. Diabetes Research Institute develops oxygen-generating biomaterial
3. Space research institute honors Sen. Hutchison with Pioneer Award
4. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
5. Minneapolis Heart Institute selected to participate in Cardiovascular Cell Therapy Research Network
6. Cary Institute Hydrofracking Forum
7. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
8. Scripps Research Institute scientists develop antidote for cocaine overdose
9. NJIT, Chinas Bengbu Glass Institute sign agreement for R&D, training
10. Merkin Family Foundation to fund next generation of Broad Institute scientists
11. TGen leads new National Institutes of Health study of brain tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 23, 2016 , ... In a new case report published today in STEM ... who developed lymphedema after being treated for breast cancer benefitted from an injection of ... dealing with this debilitating, frequent side effect of cancer treatment. , Lymphedema ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology: